Genentech arthritis drug Actemra expanded indications

A few days ago, Genentech drug Actemra rheumatoid arthritis treatment have the latest FDA-approved indications. Actemra is a human IL-6 receptor monoclonal antibody inhibiting drug class, the latest approved for those with one or more tumor necrosis factor antagonists in an inadequate response - severe active rheumatoid arthritis in adult patients.

FDA made the decision based on a randomized, double-blind, placebo-controlled trial data type Ⅲ, confirmed these patients using Actemra + MTX combination therapy for one year after treatment, in terms of preventing joint damage more effective than placebo. You can find a good Human echinococcus antibody IgG ELISA Kit in cusabio. visit this link: http://www.cusabio.com/ELISA_Kit-114582/